Search

everythinglearnresearchcommunity

for

Search:↓

A 23-year-old male has been using oral finasteride and topical minoxidil for 14 months, along with derma stamping and vitamins, but is considering switching to dutasteride due to dissatisfaction with progress. Users suggest cutting hair shorter to better track progress, and some recommend adding dutasteride and possibly a hair transplant in the future.

Hair loss treatments like finasteride, minoxidil, and ketoconazole shampoo are discussed humorously, with skepticism about future cures. Users express frustration over the lack of a permanent solution and joke about investing in stocks or using time travel to solve baldness.

A 24 year old male struggling with the physical and mental effects of balding, being short, and having a micropenis. Suggested treatments include taking medications such as finasteride and minoxidil, lifting weights, and trying not to compare himself to others.

Finasteride and dutasteride may not significantly impact meibomian gland function since these glands do not rely on DHT. Some users report dry eyes and other side effects from finasteride, but these may be influenced by other factors or medications.

People are discussing obtaining and testing PP405 for hair loss treatment, with concerns about its purity and effectiveness. Some are considering delaying hair transplants, while others suggest using existing treatments like finasteride and minoxidil.

A 3 year journey of hair loss, with recession and diffuse thinning; the user has been taking finasteride for 3 years and is now switching to dutasteride and oral minoxidil, and may start using topical minoxidil soon.

A user noticed deeper facial wrinkles since starting oral minoxidil in February 2023 and is concerned about its effects on collagen production. Other factors include past accutane use, high stress, poor sleep, and COVID-19.

The user has been using finasteride for over two years with mixed results and is considering starting dutasteride and oral minoxidil, though both are hard to obtain. They are also contemplating a hair transplant in the future due to diffuse thinning.

RU58841, an anti-androgenic compound, showed early promise for treating alopecia but faced challenges after its patent in 1997. Despite advancing to Phase II trials, safety concerns and financial struggles led Aventis to abandon its development. Proskelia, which later merged into ProStrakan, couldn't prioritize the drug, leading to its eventual stagnation and failure to reach the market.

Probiotics like L. reuteri ATCC PTA 6475 and B. longum BB536 may improve hair growth and density by reducing inflammation and reversing DHT damage. The user is trialing these probiotics personally, ordering them from the U.S. to Canada, and plans to continue if no adverse effects occur.

An 18-year-old noticed significant hairline recession and is concerned about further hair loss. They plan to improve their lifestyle and are advised to use finasteride and minoxidil and consult a dermatologist.

A user experienced severe sexual side effects and man boobs after 11 months of finasteride use, despite initial positive results for hair growth. They are discontinuing finasteride and caution others about potential risks, suggesting that side effects may be more common than reported.

The user shared their successful hair regrowth journey using a combination of oral Dutasteride and a topical mix of Finasteride, Minoxidil, Tretinoin, and Ketoconazole. They experienced no side effects and noted significant improvement, except for one persistent thinning area.

The user noticed new dark hairs growing in previously bald areas after using oral finasteride and minoxidil for a month. They are pleased with the progress and find it interesting, even though they are content with a shaved head.

Several users shared their experiences with hair loss treatments, including Minoxidil, Finasteride, and microneedling, reporting varying degrees of hair regrowth. Despite some skepticism, users noted visible improvements over time, with some considering hair transplants as a future option.

PP405 is a potential hair loss treatment showing promise, especially for men with severe balding. Some are hopeful it will be a game-changer for those who cannot tolerate finasteride or minoxidil, despite skepticism about the outcomes.

Soy consumption may help prevent androgenic alopecia, but it can decrease sexual drive in some men. There is a connection between soy and androgenic alopecia, suggesting a potential protective effect.

The user has been using Minoxidil and finasteride for a year with good progress but is now experiencing increased hair shedding. They are concerned and questioning if this is normal or a cause for worry.

SCUBE3 and GT20029 are potential treatments for hair loss, with SCUBE3 stimulating hair growth and GT20029 protecting against DHT. A combined approach using SCUBE3, finasteride or dutasteride, and later GT20029 could provide a comprehensive treatment for androgenetic alopecia.

A user experienced unexpected hormone test results after 7 months on 1mg daily finasteride, noting a decrease in estradiol despite expectations of an increase. Other users suggested that hormone responses can vary and that finasteride might still be effective if DHT levels are within range, while also mentioning factors like circadian rhythm and stress that could impact results.

A poem humorously suggests hope for a new hair loss treatment, PP405, while users debate the effectiveness and side effects of current treatments like Finasteride. Concerns are raised about Finasteride's side effects, especially for young users, and skepticism about new treatments is expressed.

Placebo hair regrowth might be influenced by propylene glycol in lotions or participants lying about using other treatments like minoxidil, finasteride, or microneedling. Being part of a study can also improve hair health due to lifestyle changes.

The user has been using finasteride, dutasteride, pyrithione zinc, and oral minoxidil to treat hair loss and has seen an increase in fine hairs on the hairline but overall thinning on the top. They are considering adding zinc and Vitamin K to their regimen and are already taking hair multivitamins with collagen.

A user is considering switching from oral to topical finasteride to reduce systemic DHT impact and is exploring ethossomal finasteride for better skin penetration and potential hair regrowth. They found ethossomal finasteride in Brazil and are seeking opinions on its effectiveness compared to other topical delivery methods.

A user is experiencing worsening hair loss despite using finasteride, PRP treatments, and supplements like vitamin D, biotin, zinc, and iron. They are seeking advice on whether to continue with finasteride, increase the dosage, or try additional PRP sessions.

The conversation humorously outlines the progression of hair loss and the increasing desperation for treatments, starting with vitamins and dermapen, moving to finasteride, then to dutasteride and experimental chemicals, and finally to acceptance with shaving or hoping for hair cloning. Some users agree with the accuracy, while others question if it's a joke.

A user experienced significant hair shedding after three years on finasteride, possibly due to stress or whey protein, and sought advice. Others suggested it might be a temporary shed, recommended monitoring for deficiencies, and mentioned adding dutasteride if needed.

A person has been using finasteride, minoxidil, OM, dutasteride, and RU58841 for hair loss for various durations but is still experiencing constant shedding and thinning. Suggestions from others include checking for potential nutritional deficiencies.

The conversation discusses the synthesis and potential use of JXL069 and PP405 for hair loss treatment, with skepticism about their effectiveness and concerns about safety. Users mention that JXL069 has shown no results in hair growth, and there is confusion about its identity and effectiveness compared to PP405.

Finasteride and Dutasteride do not cause depression or "Post Finasteride Syndrome," with concerns often linked to the nocebo effect and preexisting mental health issues. The EU is unlikely to ban these drugs, but access may become more restricted due to ongoing debates.